In connection with the Company's preferential rights issue and directed issue of units, carried out in September 2024, 3,683,814 warrants of series TO2 were issued. Holders of TO2 have the right to subscribe for one (1) new share in Curasight at a price of DKK 11.50 per share during the exercise period, which runs until the 5^th of December 2024.

In order for warrants not to expire without value, the holder is required to subscribe for new shares, by exercising warrants, no later than on the 5^th of December 2024, or sell warrants no later than on the 3^rd of December 2024. However, please note that some banks have earlier deadlines for the exercise of warrants, e.g., 4^th of December 2024 at Nordnet.

An information brochure about the Company and the offer is available on the respective websites of Curasight (www.curasight.com) and Sedermera Corporate Finance AB (www.sedermera.se). Complete terms and instructions for warrants of series TO2 are available on the Company's website.

Advisors

Sedermera Corporate Finance AB is the Company's financial advisor in connection with the capitalization. DLA Piper is the Company's legal advisor and Danske Bank is the settlement agent.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

For more information regarding the warrants, please contact:

Sedermera Corporate Finance AB

Phone: +46 40 615 14 10

E-mail: cf@sedermera.se

www.sedermera.se

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.